11/11/14: How can we best advance the science of patient input to improve the efficiency of the drug development and regulatory review process?

Back to Top

Contributors:

                
Marc M. Boutin, J.D., Executive Vice President & Chief Operating Officer, National Health Council
Robert Metcalf, Ph.D., Vice President, Global Regulatory Affairs – US & Global Medical Quality, Eli Lilly and Company
Peter L. Saltonstall, President and CEO, NORD
Sascha Haverfield , VP, Scientific and Regulatory Affairs, PhRMA
Ryan Fischer, Vice President of Advocacy and Community Outreach, Parent Project MD
Sharon Terry , President and CEO, Genetic Alliance
Kim McCleary, Director of Strategic Initiatives, FasterCures
John F P Bridges, Ph.D., Associate Professor, Johns Hopkins

Join The Conversation

10/29/14: What can be done across the health care community to best respond to infectious diseases like Ebola?

Back to Top

Contributors:

              
Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson
Donna Altenpohl, Vice President of Public Policy, GlaxoSmithKline
Andrew MacCalla, Director of International Programs and Emergency Response, Direct Relief
Erin Mullen, Executive Director, Rx Response
Dr. Bill Chin, EVP, Scientific & Regulatory Affairs, PhRMA
Mark Mosely, VP of Global Essential Medicines, Supplies and Services , Map International
John P. Howe III, M.D., President and CEO, Project HOPE

Join The Conversation

10/15/14: PhRMA was excited to participate in the Turning the Tide Against Cancer national conference. Watch participants share their thoughts on scientific advances in cancer treatments.

Back to Top

Contributors:

          
Newton Crenshaw, Vice President, Lilly Oncology Global Business Development and Advocacy, Eli Lilly and Company
Linda House, Executive Vice President of External Affairs, Cancer Support Community
Leonard Lichtenfeld, M.D., MACP, Deputy Chief Medical Officer, American Cancer Society
Stephen Eck, M.D., Ph.D.,Vice President and Global Head of Oncology, Astellas Pharma Global Dev
Roy Herbst, M.D., PhD.; Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology; Associate Director for Translational Research; Clinical Research, Yale Cancer Center

Join The Conversation

09/22/14: Which of the findings of the PhRMA National Health Survey was most surprising to you, and why?

Back to Top

Contributors:

    
Geoffrey Garin, President, Hart Research Associates
Brandon Leonard, Director of Strategic Initiatives, Men's Health Network

Join The Conversation

09/09/14: What are you excited about in the fight against HIV/AIDS?

Back to Top

Contributors:

          
Lawrence Stallworth, Mobile Health Services Specialist, AIDS Taskforce: Greater Cleveland
Kathie Hiers, CEO, AIDS Alabama
Phill Wilson, President and CEO, Black AIDS Institute
Travis Sherer, PA-C, AAHIVS, GLMA
Bill Arnold, Founding Director, CANN

Join The Conversation

07/30/14: We’ve seen great strides to treat arthritis and related diseases. How do we continue to make headway to improve the lives of patients?

Back to Top

Contributors:

            
James P. Sullivan, Ph.D., VP, Pharmaceuticals Discovery, AbbVie
Stephen I. Katz, Director, NIAMS
Amanda Niskar, National Scientific Director, Arthritis Foundation
Christopher F. Smith, CEO, Arthritis Foundation, GLR
Gabriela Lavezzari, AVP, Scientific Affairs , PhRMA
NPF, Partner, Arthritis Contributor

Join The Conversation

07/24/14: What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Back to Top

Contributors:

          
Amy Miller, Executive Vice President, PMC
Raju Kucherlapati, Professor, Department of Genetics, Harvard Medical School
Donna R. Cryer, JD, President & CEO, Global Liver Institute
Randy Burkholder, VP, Policy, PhRMA
Mark Richards, Senior Vice President, Management Supervisor, KRC Research

Join The Conversation

06/17/14: As Americans live longer, how can we tackle aging as a major risk factor for chronic disease?

Back to Top

Contributors:

                
Bob Blancato , Executive Director, NANASP
Cynthia A. Bens, Vice President, Public Policy, Alliance for Aging Research
Dorothy Leone-Glasser, President and CEO, ARxC
Jamesetta Smith, President, Lupus Foundation AR
Paul Downey, President and Chief Executive Officer, Serving Seniors
Thair Phillips, President, RetireSafe
Rob Gundermann, Public Policy Director, ADAW
James Adams, Chairman, Granite State Taxpayers

Join The Conversation

06/11/14: How are patients with chronic conditions who have exchange coverage affected by high out-of-pocket costs for medicines?

Back to Top

Contributors:

                
Margaret Barton-Burke, President, ONS
Angela Ostrom, VP, Public Policy & Advocacy, Epilepsy Foundation
Carl Schmid, Deputy Executive Director, The AIDS Institute
Virginia T. Ladd, President , AARDA
Brian Hujdich, Executive Director, HealthHIV
Bob Blancato , Executive Director, NANASP
Lawrence A. LaMotte, Vice President, Public Policy, Immune Deficiency Foundation
Colon Cancer Alliance, Colon Cancer Alliance, Colon Cancer Alliance

Join The Conversation

06/05/14: We all want to better prevent, treat and cure the many forms of cancer. How close is the collaborative research ecosystem to achieving these goals, and what do we have to do to get there?

Back to Top

Contributors:

      
Josh Schafer, MSc. MBA, Vice President, Oncology Global Marketing Strategy, Astellas Pharmaceuticals
Rafael Amado, Senior Vice President, Oncology R&D, GlaxoSmithKline
Salvatore Alesci , VP, Scientific & Regulatory Affairs, PhRMA

Join The Conversation

Pages